Diabetes Research and Clinical Practice
Volume 73, Issue 3 , Pages 227-234 , September 2006

The role of polyol pathway in high glucose-induced endothelial cell damages

Received 28 April 2005 ,Revised 11 November 2005 ,Accepted 13 February 2006.

References 

  1. Kannnel WB, McGee DL. Diabetes and cardiovascular disease, the Framingham study. JAMA. 1979;241:2035–2038
  2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–444
  3. Sakata N, Meng J, Takebayashi S. Effect of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J. Atheroscler. Thromb. 2000;3:169–176
  4. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm. 2000;60:149–193
  5. Mashima R, Witting PK, Stocker R. Oxidants and antioxidants in atherosclerosis. Curr. Opin. Lipidol. 2001;4:411–418
  6. Sakamoto N, Kinoshita JH, Kador PF, Hotta N. Polyol Pathway and its Role in Diabetic Complications. Amsterdam: Elsevier Science B.V.; 1988;
  7. Hotta N, Sakamoto N. Aldose reductase inhibitors. In:  Alberti KGMM,  Krall LP editor. The Diabetes Annual 5. Amsterdam: Elsevier Science B.V.; 1990;p. 330–361
  8. Naruse K, Nakamura J, Hamada Y, Nakayama M, Chaya S, et al. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp. Eye Res. 2000;71:309–315
  9. Bhatnagar A, Srivastava SK. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. Biochem. Med. Metabol. Biol. 1992;48:91–121
  10. Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetes complications. Diabetes Metab. Rev. 1988;4:323–337
  11. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetes complications. Pharmacol. Rev. 1988;50:21–33
  12. Gabbay KH. The sorbitol pathway and the complications of diabetes. N. Engl. J. Med. 1973;288:831–836
  13. Hamada Y, Kitoh R, Raskin P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes. 1991;40:1233–1240
  14. Dent MT, Tebbs SE, Gonzalez AM, Ward JD, Wilson R. Neutrophil aldose reductase activity and its association with established diabetic microvascular complications. Diabetes Med. 1991;8:439–442
  15. Endo T, Iwata N, Inazu N, Hara S, Kano S, Kuriiwa F, et al. Interindividual variability of hepatic carbonyl reductase levels in Japanese. In:  Bernhard J,  Bonte W editor. Advancement of Forensic Science. Berlin: Verlag Chemie; 1995;p. 27–31
  16. Gonzalez RG, Barnett P, Aguayo J, Cheng H-M, Chylack LT. Direct measurement of polyol pathway activity in the ocular lens. Diabetes. 1984;33:196–199
  17. Chandra D, Jackson EB, Ramana KV, Kelley R, Srivastava SK, Bhatnagar A. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes. Diabetes. 2002;51(10):3095–3101
  18. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium–potassium-ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med. 1987;316(5):599–606
  19. Kinoshita JH, Merola LO, Satoh K, Dikmac E. Osmotic changes caused by accumulation of dulcitol in the lenses of rats fed with galactose. Nature. 1962;194:1085–1087
  20. Kashiwagi A, Asahina T, Ikebuchi M, Tanaka Y, Takagi Y, Nishio Y, et al. Abnormal glutathione metabolism and increased cytotoxicity caused by H2O2 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia. 1994;37:262–269
  21. Williamson JR, Cheng K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801–813
  22. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia. 1992;35:1011–1019
  23. Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M. Effects of a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro [chroman-4,4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism. 1992;41(10):1081–1086
  24. Jaffe EA, Nachmann RI, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 1973;52:2745–2746
  25. Gordon O, Guerrant C, Moss W. Determination of monosaccharides as aldononitrite, O-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal. Chem. 1984;56:633–638
  26. Wiechelman K, Braun R, Fitzpatrick J. Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation. Anal. Biochem. 1988;175:231–237
  27. Wang X, Zelenski NG, Yang J, et al. Cleavage of sterol regulatory element binding protein (SREBPs) by CPP32 during apoptosis. EMBO J. 1996;15:1012–1020
  28. Kumar S. The apoptotic cysteine protease CPP32. Int. J. Biochem. Cell Biol. 1997;29:393–396
  29. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. U.S.A. 1988;85:6465–6467
  30. Kasai H, Crain PF, Kuchino Y, Nishimura S, Ootsuyama A, Tanooka H. Formation of 8-hydroxy-2′-deoxyguanosine moiety in cellular DNA by agents producting oxygen radicals and evidence for its repair. Carcinogenesis. 1986;7:1849–1851
  31. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, Vlassara H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes. 2003;52:2805–2813
  32. Leinonen J, Lehtimaki T, Toyokuni S, Okada K, Tanaka T, Hirai H, et al. New biomarker evidence of oxidative DNA damage in patients with non-insurin-dependent diabetes mellitus. FEBS Lett. 1997;417:150–152
  33. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab. Invest. 1997;76:365–374
  34. Malin R, Rantalaiho V, Huang XH, Wirta O, Pasternack A, Leinonen JS, et al. Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects. Hum. Genet. 1999;105:179–180
  35. Mizutani K, Ikeda K, Nishikata T, Yamori Y. Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J. Hypertens. 2000;18:1833–1840
  36. Inoue T, Inoue K, Maeda H, Takayanagi K, Morooka S. Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients. Clin. Chim. Acta. 2001;305:115–121
  37. Barnett PA, Gonzalez RG, Chylack LT, Cheng HM. The effect of oxidation on sorbitol pathway kinetics. Diabetes. 1986;35:426–432
  38. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, et al. Aldose reductase inhibition counteracts oxidative–nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes. 2005;54:234–242
  39. Mlakar A, Batna A, Dudda A, Spiteller G. Iro (II) ions induced oxidation of ascorbic acid and glucose. Free Radical Res. 1996;25:525–539
  40. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry. 1995;34:3702–3709
  41. Shangari N, O’Brien PJ. The cytotoxic mechanism of glyoxal involves oxidative stress. Biochem. Pharmacol. 2004;68:1433–1442
  42. Loidl-Stahlhofen A, Spiteller G. Alpha-hydroxyaldehydes, products of lipid peroxidation. Biochim. Biophys. Acta. 1994;1211:156–160
  43. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc. Natl. Acad. Sci. U.S.A. 1989;86:9697–9701
  44. Halliwell B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radical Res. 1996;25:57–74
  45. Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care. 2003;26:1507–1512
  46. Nakanishi S, Suzuki G, Kusunoki Y, Kimura K, Egusa G, Kohno N. Increasing of oxidative stress from mitochondria in type 2 diabetic patients. Diabetes Metab. Res. Rev. 2004;20:399–404
  47. Suzuki S, Hinokio Y, Komatsu K, Ohtomo M, Onoda M, Hirai S, et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res. Clin. Pract. 1999;45:161–168
  48. Miyashita Y, Shirai K, Ito Y, Watanabe J, Urano Y, Murano T, et al. Cytotoxicity of some oxysterols on human vascular smooth muscle cells was mediated by apoptosis. J. Atheroscler. Thromb. 1997;4:73–78
  49. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J. 2004;18:1209–1218
  50. Suzuki T, Sekido H, Kato N, Nakayama Y, Yabe-Nishimura C. Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway. J. Neurochem. 2004;91:1430–1438
  51. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 1996;274:782–784
  52. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–1683
  53. Chu Z-L, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl. Acad. Sci. U.S.A. 1997;94:10057–10062

PII: S0168-8227(06)00062-3

doi: 10.1016/j.diabres.2006.02.010

Diabetes Research and Clinical Practice
Volume 73, Issue 3 , Pages 227-234 , September 2006

Article Tools

* Image Usage & Resolution